SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives and immunotherapies to treat fungal and
other infections, announced that the company has named Taylor Sandison,
M.D., M.P.H., its vice president, clinical development, to the position
of acting chief medical officer, effective September 2, 2016. Dr.
Sandison will replace Dirk Thye, M.D., Cidara’s previous chief medical
officer, who has accepted a CEO position at a non-competing San
Francisco Bay Area-based biotech company. Dr. Thye will continue to
assist Cidara as a consultant.
“We wish Dirk all the best as he pursues his new endeavor, and we extend
our sincere gratitude for his exceptional work in spearheading our
antifungal development programs,” said Jeffrey Stein, Ph.D., president
and chief executive officer of Cidara. “We are pleased to have a highly
experienced internal replacement in Taylor, allowing for a seamless
transition of responsibilities. Taylor’s extensive experience has
already been extremely valuable to our progress.”
Dr. Sandison has been with Cidara since October 2015. Prior to joining
the company, he served as senior medical director at Cubist
Pharmaceuticals, Inc. from July 2014 to January 2015 and then, following
Merck’s acquisition of Cubist, as senior medical director at Merck from
February to October 2015. Dr. Sandison has also held positions at Trius
Therapeutics and Novartis Diagnostics, and served as a member of the
faculty in the Department of Medicine at both Stanford University and
the University of Washington. He received B.S. and B.A. degrees from
Dartmouth College, and M.D. and M.P.H. degrees from the University of
Washington. He completed residency training at the University of
Colorado and fellowship training at the University of Washington. Dr.
Sandison holds board certifications in Infectious Diseases and Internal
Medicine.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel anti-infectives
for the treatment of diseases that are inadequately addressed by current
standard-of-care therapies. Cidara’s initial product portfolio comprises
two formulations of the company’s novel echinocandin, CD101. CD101 IV is
being developed as a once-weekly, high-exposure therapy for the
treatment and prevention of serious, invasive fungal infections. CD101
topical is being developed for the treatment and prevention of
vulvovaginal candidiasis (VVC), a prevalent mucosal infection. In
addition, Cidara has developed a proprietary immunotherapy platform,
Cloudbreak™, designed to create compounds that direct a patient’s immune
cells to attack and eliminate pathogens that cause infectious disease.
Cidara is headquartered in San Diego, California. For more information,
please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding Cidara’s clinical management change and Dr.
Sandison’s ability to effectively replace Dr. Thye. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in the United States and
foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005355/en/
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Mike Beyer, 312-961-2502
mikebeyer@sambrown.com
